NSC 109555 ditosylateSelective Chk2 inhibitor CAS# 66748-43-4 |
- Dofetilide
Catalog No.:BCC3770
CAS No.:115256-11-6
- Repaglinide
Catalog No.:BCC2504
CAS No.:135062-02-1
- Dronedarone
Catalog No.:BCN2176
CAS No.:141626-36-0
- TRAM-34
Catalog No.:BCC1122
CAS No.:289905-88-0
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 66748-43-4 | SDF | Download SDF |
| PubChem ID | 12449850 | Appearance | Powder |
| Formula | C33H40N10O7S2 | M.Wt | 752.86 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | DDUG | ||
| Solubility | Soluble to 10 mM in DMSO | ||
| Chemical Name | 1,3-bis[4-[(E)-N-(diaminomethylideneamino)-C-methylcarbonimidoyl]phenyl]urea;4-methylbenzenesulfonic acid | ||
| SMILES | CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CC(=NN=C(N)N)C1=CC=C(C=C1)NC(=O)NC2=CC=C(C=C2)C(=NN=C(N)N)C | ||
| Standard InChIKey | DIQGNVANOSOABS-XMDRLFCYSA-N | ||
| Standard InChI | InChI=1S/C19H24N10O.2C7H8O3S/c1-11(26-28-17(20)21)13-3-7-15(8-4-13)24-19(30)25-16-9-5-14(6-10-16)12(2)27-29-18(22)23;2*1-6-2-4-7(5-3-6)11(8,9)10/h3-10H,1-2H3,(H4,20,21,28)(H4,22,23,29)(H2,24,25,30);2*2-5H,1H3,(H,8,9,10)/b26-11+,27-12+;; | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Selective, reversible, ATP-competitive Chk2 inhibitor (IC50 = 0.2 μM) that displays no effect on a range of other kinases including Chk1 (IC50 > 10 μM). Inhibits histone H1 phosphorylation (IC50 = 0.24 μM) and attenuates mitochondrial ATP synthesis. Exhibits antiproliferative activity in a number of leukemias in vivo. |
NSC 109555 ditosylate Dilution Calculator
NSC 109555 ditosylate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.3283 mL | 6.6413 mL | 13.2827 mL | 26.5654 mL | 33.2067 mL |
| 5 mM | 0.2657 mL | 1.3283 mL | 2.6565 mL | 5.3131 mL | 6.6413 mL |
| 10 mM | 0.1328 mL | 0.6641 mL | 1.3283 mL | 2.6565 mL | 3.3207 mL |
| 50 mM | 0.0266 mL | 0.1328 mL | 0.2657 mL | 0.5313 mL | 0.6641 mL |
| 100 mM | 0.0133 mL | 0.0664 mL | 0.1328 mL | 0.2657 mL | 0.3321 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- MeBIO
Catalog No.:BCC3898
CAS No.:667463-95-8
- BIO-acetoxime
Catalog No.:BCC6076
CAS No.:667463-85-6
- GSK-3 Inhibitor IX (BIO)
Catalog No.:BCC4510
CAS No.:667463-62-9
- PG 931
Catalog No.:BCC6363
CAS No.:667430-81-1
- 5-Hydroxy-7-acetoxyflavone
Catalog No.:BCN4217
CAS No.:6674-40-4
- DBU
Catalog No.:BCC2840
CAS No.:6674-22-2
- 3-Nitro-L-tyrosine ethyl ester hydrochloride
Catalog No.:BCN1384
CAS No.:66737-54-0
- E-64
Catalog No.:BCC1222
CAS No.:66701-25-5
- 8-Bromo-7-(but-2-yn-1-yl)-3-methyl-1H-purine-2,6(3H,7H)-dione
Catalog No.:BCC8786
CAS No.:666816-98-4
- Polygalacin D
Catalog No.:BCN3861
CAS No.:66663-91-0
- Platycodin D2
Catalog No.:BCN3847
CAS No.:66663-90-9
- Esculentoside H
Catalog No.:BCN2795
CAS No.:66656-92-6
- Diosbulbin D
Catalog No.:BCN4218
CAS No.:66756-57-8
- 6,8-Diprenylorobol
Catalog No.:BCN4602
CAS No.:66777-70-6
- Esculin Sesquihydrate
Catalog No.:BCC8324
CAS No.:66778-17-4
- Platycodin A
Catalog No.:BCN7997
CAS No.:66779-34-8
- Impurity B of Calcitriol
Catalog No.:BCC1645
CAS No.:66791-71-7
- Syringaresinol-di-O-glucoside
Catalog No.:BCN2600
CAS No.:66791-77-3
- (+/-)-Forbesione
Catalog No.:BCN6423
CAS No.:667914-50-3
- Hernandezine
Catalog No.:BCN7793
CAS No.:6681-13-6
- Jatrorrhizine chloride
Catalog No.:BCN4956
CAS No.:6681-15-8
- Magnoflorine chloride
Catalog No.:BCN2405
CAS No.:6681-18-1
- Linagliptin (BI-1356)
Catalog No.:BCC2110
CAS No.:668270-12-0
- LDN 57444
Catalog No.:BCC2087
CAS No.:668467-91-2
Oroxylin A reverses P-glycoprotein-mediated multidrug resistance of MCF7/ADR cells by G2/M arrest.[Pubmed:23470866]
Toxicol Lett. 2013 May 23;219(2):107-15.
Oroxylin A is a naturally occurring monoflavonoid isolated from the root of Scutellaria baicalensis Georgi, which has been used in traditional Chinese medicine for its anti-tumor, anti-inflammatory and anti-bacterial properties. The purpose of this study is to investigate the reversal effect and the fundamental mechanisms of oroxylin A in MCF7/ADR cells. Data indicated that oroxylin A showed strong reversal potency in MCF7/ADR cells and the reversal fold (RF) reached 4.68. After treatment with oroxylin A, MCF7/ADR cells displayed reduced functional activity and expression of MDR1 at both the protein and mRNA levels. Meanwhile, oroxylin A induced cells G2/M arrest in a concentration-dependent manner by increasing the expression of p-Chk2 (Thr68). Moreover, western blot and EMSA assays were used to reveal the inhibition of NF-kappaB in nucleus and the suppression of NF-kappaB binding activity by oroxylin A. NSC 109555 ditosylate-Chk2 inhibitor partly dismissed G2/M arrest induced by oroxylin A, reversed the increased trend of p-Chk2 and p-P53 (Ser20), inhibited the decreasing effect of oroxylin A on the expression of P-gp and decreased the reversal fold of 90 muM oroxylin A from 4.68 fold to 1.73 fold. In conclusion, we suggested that oroxylin A reversed MDR by G2/M arrest and the underlying mechanism attributed to the suppression of P-gp expression via Chk2/P53/NF-kappaB signaling pathway.
Identification of a Bis-guanylhydrazone [4,4'-Diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a novel chemotype for inhibition of Chk2 kinase.[Pubmed:17616632]
Mol Pharmacol. 2007 Oct;72(4):876-84.
Chk2 is a protein kinase involved in the ATM-dependent checkpoint pathway (http://discover.nci.nih.gov/mim). This pathway is activated by genomic instability and DNA damage and results in either cell cycle arrest, to allow DNA repair to occur, or cell death (apoptosis). Chk2 is activated by ATM-mediated phosphorylation and autophosphorylation and in turn phosphorylates its downstream targets (Cdc25A, Cdc25C, BRCA1, p53, Hdmx, E2F1, PP2A, and PML). Inhibition of Chk2 has been proposed to sensitize p53-deficient cells as well as protect normal tissue after exposure to DNA-damaging agents. We have developed a drug-screening program for specific Chk2 inhibitors using a fluorescence polarization assay, immobilized metal ion affinity-based fluorescence polarization (IMAP). This assay detects the degree of phosphorylation of a fluorescently linked substrate by Chk2. From a screen of over 100,000 compounds from the NCI Developmental Therapeutics Program, we identified a bis-guanylhydrazone [4,4'-diacetyldiphenylureabis(guanylhydrazone); NSC 109555] as a lead compound. In vitro data show the specific inhibition of Chk2 kinase activity by NSC 109555 using in vitro kinase assays and kinase-profiling experiments. NSC 109555 was shown to be a competitive inhibitor of Chk2 with respect to ATP, which was supported by docking of NSC 109555 into the ATP binding pocket of the Chk2 catalytic domain. The potency of NSC 109555 was comparable with that of other known Chk2 inhibitors, such as debromohymenialdisine and 2-arylbenzimidazole. These data define a novel chemotype for the development of potent and selective inhibitors of Chk2. This class of drugs may ultimately be useful in combination with current DNA-damaging agents used in the clinic.
Potentiation of the antimitochondrial and antiproliferative effects of bis(guanylhydrazones) by phenethylbiguanide.[Pubmed:6896674]
Cancer Res. 1982 Sep;42(9):3592-5.
The ability of methylglyoxal-bis(guanylhydrazone) (MGBG) and 4,4'-diacetyldiphenylurea-bis(guanylhydrazone) to interact with the hypoglycemic agent, phenethylbiguanide (DBI), in affecting the bioenergetic functions of isolated rat liver mitochondria was studied. DBI was found to increase markedly the inhibitory effect of either 4,4'-diacetyldiphenylurea-bis(guanylhydrazone) or MGBG on respiration of isolated rat liver mitochondria. Conversely, these bis(guanylhydrazones) enhanced the inhibitory potency of DBI and increased the apparent affinity of mitochondria for the drug. As with MGBG and 4,4'-diacetyldiphenylurea-bis(guanylhydrazone), the potassium cationophore, valinomycin, increased the sensitivity of mitochondrial respiration to DBI. It is suggested that the enhancement of bis(guanylhydrazone) inhibition of mitochondrial respiration by DBI involves inhibition of proton fluxes across the inner mitochondrial membrane and the subsequent alkalinization of the mitochondrial matrix. This drug interaction was extended to the level of antiproliferative activity in which DBI was found to potentiate the growth-inhibitory effects of MGBG on murine L1210 leukemia in vivo.
